At what enterprise value was GLOBAL DIAGNOSTICS acquired in 2020?

During the acquisition of GLOBAL DIAGNOSTICS by MEDICA GROUP in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 10M - 30M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GLOBAL DIAGNOSTICS when it was acquired by MEDICA GROUP?

The estimated EV/EBITDA multiple for GLOBAL DIAGNOSTICS is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was GLOBAL DIAGNOSTICS acquired by MEDICA GROUP?

GLOBAL DIAGNOSTICS was acquired by MEDICA GROUP in 2020.

What was the revenue of GLOBAL DIAGNOSTICS at the time of the deal?

The revenue of GLOBAL DIAGNOSTICS at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of GLOBAL DIAGNOSTICS during the acquisition?

GLOBAL DIAGNOSTICS's EBITDA is estimated to be in the range of 0M - 5M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GLOBAL DIAGNOSTICS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLOBAL DIAGNOSTICS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://medica.co.uk/wp-content/uploads/2020/10/Medica-Group-PLC-Global-Diagnostics-Acquisition-Market-Presentation-4Nov2020.pdf

← DATABASE

Home Database Healthcare & PharmaGLOBAL DIAGNOSTICS

11/2020

GLOBAL DIAGNOSTICS acquired by MEDICA GROUP

IRELAND Health Providers / Outpatient Care / Radiology EV 10M - 30M EUR

Context

Global Diagnostics Ireland, which operates around 50 clinical centers across Ireland, has been acquired by Medica Group. For Medica, this acquisition represents a diversification of its customer base and geographic activities, as well as entry into a new market: ophthalmology and retinopathy screening.

GLOBAL DIAGNOSTICS, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Global Diagnostics Ireland functions as a high-fidelity diagnostic partnership platform, specializing in the delivery of managed radiology and teleradiology services to both public and private healthcare sectors. The organization operates a sophisticated technical infrastructure that encompasses plain film, ultrasound, CT, and MRI managed-service solutions across dozens of clinical sites. Rather than offering generic diagnostic support, the firm utilizes its specialized technical operational depth to manage high-stakes national screening initiatives, particularly for diabetic retinopathy. Its strategy is anchored in being an embedded clinical partner for the Irish Health Service Executive (HSE), utilizing a network of certified specialist radiologists to mitigate the systemic undersupply of regional diagnostic talent. The entity facilitates the transition of complex clinical imaging into a streamlined, tech-enabled reporting workflow, ensuring that critical diagnostic data is accessible and actionable for hospital teams.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2020	RADIOLOGY PARTNERS	MEDNAX RADIOLOGY SOLUTIONS	UNITED STATES	Radiology
12/2020	ANTIN INFRASTRUCTURE	HIPPOCRATES (LAF - LA FARMACIA)	ITALY	Pharmacy
11/2020	L CATTERTON	ALLIANCE ANIMAL HEALTH	UNITED STATES	Vet Clinics
11/2020	APHEON (EX ERGON)	VIDACURA	GERMANY	Nursing Homes
11/2020	DWS GROUP	MEDIPASS	ITALY	Radiology
11/2020	ARDIAN	INOVIE GROUP	FRANCE	Labs (Biology)
10/2020	KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS	ELSAN	FRANCE	Clinics / Hospitals
10/2020	INFRATIL	QSCAN GROUP	AUSTRALIA	Radiology
10/2020	THE VISTRIA GROUP / CENTERBRIDGE PARTNERS	HELP AT HOME	UNITED STATES	Nursing Homes
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology

REFERENCES

Valuation range: EV 10M - 30M EUR

Revenue range: 5M - 25M EUR

EBITDA range: 0M - 5M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLOBAL DIAGNOSTICS by MEDICA GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: medica group